SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes PAI at Jubilant Pharmova’s arm's facility at Roorkee

02 Aug 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded pre-approval inspection (PAI) at Jubilant Pharmova’s stepdown subsidiary -- Jubilant Generics' solid dosage formulations facility at Roorkee site, India.  The USFDA has issued 4 observations pursuant to the completion of audit. The company will submit an action plan on the observations.

The site’s revenue from the US market in the trailing twelve-month period (July 2024 to June 2025) is less than one percent of Jubilant Pharmova revenues in the same period.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

946.30 19.65 (2.12%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×